United States Patent 7,553,818 (Phentermine + Topiramate) Patent Scope, Claim Construction, and US Patent Landscape
US Patent 7,553,818 protects a combination method-of-use for weight loss using phentermine plus topiramate administered continually over a defined period, with topiramate dose ranges selected to prevent loss of phentermine effectiveness over time. The claims are structured around four phentermine strengths (8 mg, 10 mg, 15 mg, 20 mg) and multiple topiramate dose thresholds and ranges (≥50 mg, 50–400 mg, ≥100 mg, ≥200 mg), with a key duration limitation (4 to 67 weeks).
This patent’s scope is primarily behavioral (treatment regimens) rather than formulation or composition claims, so infringement hinges on whether an accused regimen administers: (i) phentermine at one of the claimed daily doses, (ii) topiramate at a claimed daily amount, and (iii) both over the claimed “significant period of time,” with the functional requirement that topiramate is selected to prevent loss of effectiveness of phentermine alone.
What does US Patent 7,553,818 claim for weight loss methods (phentermine and topiramate together)?
Core independent claim structure (Claim 1 / Claim 7 / Claim 13 / Claim 19)
Each independent claim follows the same architecture:
- Weight loss method for a subject in need thereof
- Continual administration of phentermine at a specified daily dose
- In combination with topiramate
- Topiramate daily amount selected to prevent the loss of effectiveness of phentermine alone
Claim 1 (8 mg phentermine)
- Phentermine: 8 mg daily
- Topiramate: daily amount selected to prevent loss of phentermine effectiveness
Claim 7 (10 mg phentermine)
- Phentermine: 10 mg daily
- Topiramate: daily amount selected to prevent loss of phentermine effectiveness
Claim 13 (15 mg phentermine)
- Phentermine: 15 mg daily
- Topiramate: daily amount selected to prevent loss of phentermine effectiveness
Claim 19 (20 mg phentermine)
- Phentermine: 20 mg daily
- Topiramate: daily amount selected to prevent loss of phentermine effectiveness
Claim limitations that drive infringement risk
- Daily phentermine strength is not generic. A regimen using a different phentermine dose may avoid literal infringement unless the doctrine of equivalents is applied and the “at least”/range language of other claims doesn’t cover it.
- Topiramate is not just co-administered. It must be “selected” for a functional purpose: preventing the loss of phentermine effectiveness when phentermine is used alone.
- “Continually over a significant period of time” matters. Independent claims use a functional/relative term; dependent claims lock it down for certain embodiments (4 to 67 weeks).
- Combination requirement is strict. The claims require topiramate in combination with phentermine during the weight loss course.
How broad are the treatment-duration and dosing limitations in US 7,553,818?
Duration
- Dependent claims specify: “from 4 weeks to 67 weeks” (Claims 2, 8, 14, 20).
This creates two infringement lanes:
- Literal coverage with duration: A regimen within 4–67 weeks is clearly within the dependent claim scope.
- Independent coverage without explicit duration: The independent claims still require “continually over a significant period of time,” which is not numerically defined in the independent claims you provided, but could be argued based on claim construction and evidence in the specification/prosecution history.
Topiramate dose thresholds and range
The claims create a ladder of topiramate coverage:
- ≥50 mg/day (Claims 3, 9, 15, 21)
- 50–400 mg/day (Claims 4, 10, 16, 22)
- ≥100 mg/day (Claims 5, 11, 17, 23)
- ≥200 mg/day (Claims 6, 12, 18, 24)
Implication for scope
- The 50–400 mg/day sub-range is the only explicit bracketed interval. The ≥100 and ≥200 thresholds are nested within ≥50 and may also fall inside 50–400 depending on the regimen. If a regimen uses topiramate above 400 mg/day, it may avoid the explicit 50–400 limitation while still potentially meeting “≥50 mg” and “≥100 mg” and “≥200 mg” depending on how a court treats the range structure across dependent claims.
- Because the independent claims you provided do not set numeric topiramate limits, the topiramate dose constraints are primarily captured through dependent claim subsets.
What is the legal effect of “topiramate selected to prevent the loss of effectiveness of phentermine alone”? (functional selection language)
The phrase “selected to prevent the loss of effectiveness of phentermine alone” introduces a functional selection limitation. That shifts the scope from mere co-administration toward whether the accused regimen satisfies the functional relationship.
Key claim-scope consequences:
- Evidence of functional purpose becomes central. In practice, infringement arguments typically lean on:
- clinical rationale in labeling or physician instructions,
- regimen selection rationale,
- and/or expert interpretation linked to the patent’s teachings.
- A regimen with the right numeric doses may still be contested if the “selected to prevent loss of effectiveness” functional element is not satisfied as construed.
- A generic or alternative-strength regimen may still be captured if it administers phentermine within the claimed dose constraints and topiramate at claimed amounts and the functional purpose is met by the regimen.
Because you provided only the claims, not the patent specification or file history, claim interpretation must be driven strictly by the intrinsic claim language you supplied.
How many distinct claimed regimen combinations are covered by US 7,553,818?
Based on the claim set you provided:
Phentermine daily dose branches (4)
- 8 mg (Claim 1)
- 10 mg (Claim 7)
- 15 mg (Claim 13)
- 20 mg (Claim 19)
Topiramate dose sub-sets (4 dependent tiers + range)
- ≥50 mg (Claims 3, 9, 15, 21)
- 50–400 mg (Claims 4, 10, 16, 22)
- ≥100 mg (Claims 5, 11, 17, 23)
- ≥200 mg (Claims 6, 12, 18, 24)
Duration locked subset (4 dependent claims)
- 4 to 67 weeks (Claims 2, 8, 14, 20)
Practical count (without double-counting overlapping dependents)
The claims cover at least 4 phentermine-strength regimens, each with topiramate thresholds/range options, and at least one duration window option. The overlap means the patent is best viewed as a regimen matrix rather than a single fixed combination.
What patents likely form the surrounding US landscape for phentermine + topiramate weight-loss regimens?
Without the rest of the family record and without Orange Book listings tied to specific NDCs, the most actionable landscape mapping you can do from claim content alone is to classify likely adjacent US patent types that commonly coexist in this therapeutic concept:
-
Method-of-use patents for:
- weight-loss regimens using phentermine/topiramate with titration or “continual administration”
- treatment durations (weeks-to-months windows)
- functional statements about “preventing tolerance” or “preventing loss of effectiveness.”
-
Dose-range patents for:
- phentermine dose strengths (your claims: 8/10/15/20 mg daily)
- topiramate dose thresholds (≥50/≥100/≥200; and explicit 50–400 mg range).
-
Formulation patents (less directly implicated by your claims):
- controlled-release combinations
- fixed-dose combinations
- extended dosing regimens.
Your claims are squarely method-of-use and dose regimen-based, so the most relevant competitive freedom-to-operate (FTO) barriers are likely other method-of-use and dose-range patents in the same concept family, not formulation chemistry patents.
Which generic entry risks exist under the US 7,553,818 regimen claim structure?
High-risk scenario (literal target)
A generic or branded competitor’s label or physician regimen instructs or effectively causes:
- phentermine at 8/10/15/20 mg daily (one of the claimed daily doses), and
- topiramate at ≥50 mg, and/or 50–400 mg, and/or ≥100 mg, and/or ≥200 mg, and
- use continually for a “significant period,” including 4–67 weeks for dependent claim coverage.
Lower-risk scenarios (avoid one claim element)
- Dose mismatch: phentermine at a daily dose outside 8/10/15/20 mg.
- Topiramate mismatch: topiramate daily dose below the claimed thresholds (for example <50 mg) or a dose that avoids the explicit 50–400 range, depending on how the court treats nested dependents.
- Duration mismatch: regimen shorter than 4 weeks.
- Functional mismatch: absence of evidence that topiramate was “selected to prevent loss of effectiveness of phentermine alone.” This is the hardest to assess purely from dose and time because the limitation is functional.
How does the claim structure affect enforceability against different business models? (label vs off-label vs combination therapy)
If a competitor markets a labeled regimen matching the claim
Enforcement risk is typically higher because the “selected” limitation is more easily supported by:
- label language,
- promotional materials,
- and prescriber instructions.
If a competitor sells components and relies on off-label prescribing
The patent is still infringed if the method is performed, but proving infringement is often fact-intensive. The presence of explicit dosage instructions aligned to the claimed doses and duration tends to raise litigation leverage.
If a competitor changes dosing/titration schedules
Any titration pattern that does not meet:
- the specific phentermine daily dose points,
- the topiramate daily amount thresholds/range,
- or the 4–67 week window,
can be used to design around literal coverage. Whether equivalents apply depends on claim construction and evidence.
Timeline and exclusivity mapping: when does this type of method patent lose exclusivity?
Your prompt provides only the claim text, not:
- patent grant date,
- filing date,
- maintenance fee status,
- or family priority.
Without those facts, an exclusivity and expiration timeline cannot be stated accurately. The same limitation applies to:
- expected Hatch-Waxman Paragraph IV windows,
- potential biologic-style exclusivity (unlikely here),
- and any interaction with Orange Book “listed patents” for specific NDCs.
Key takeaways
- US 7,553,818 is a method-of-use weight loss patent covering phentermine + topiramate administered continuously over a significant period, with topiramate functionally selected to prevent loss of phentermine effectiveness when used alone.
- Claim scope is anchored by four phentermine daily doses: 8/10/15/20 mg.
- Dependent claims lock in duration (4–67 weeks) and topiramate dosing via ≥50 mg, 50–400 mg, ≥100 mg, and ≥200 mg thresholds/ranges.
- Infringement analysis is a three-element test: phentermine dose + topiramate dose + time period, plus a functional selection limitation.
- Generic entry risk is highest where a competitor’s regimen or label drives physicians to use the claimed dose matrix over the claimed duration.
FAQs
1) Does US 7,553,818 require a fixed-dose combination product, or is co-administration enough?
The claims require “administering” phentermine and topiramate “in combination,” which covers concurrent regimen use. They do not, from the claim text provided, require a single fixed-dose dosage form.
2) Can a regimen using phentermine 8 mg avoid infringement by using topiramate below 50 mg?
If topiramate is below the claimed “selected” thresholds captured in the dependent claims (and if that leads to failing the “selected to prevent loss of effectiveness” limitation as construed), it can reduce or avoid coverage.
3) What happens if topiramate is 300 mg/day, within 50–400 mg/day?
It falls within the explicit 50–400 mg/day dependent claim bracket, assuming the other elements (phentermine dose and duration) are met.
4) Is 3 weeks of use covered under the duration limitation?
Dependent claims explicitly recite 4–67 weeks. A 3-week regimen avoids those dependent duration limitations; independent claims still require “continually over a significant period of time,” which may still be argued based on claim construction and evidence.
5) Does “preventing loss of effectiveness” broaden the scope beyond dose and time?
Yes. It adds a functional limitation that can be contested based on the claimed rationale for selection and the clinical effect of the combined regimen versus phentermine alone.
References (APA)
- United States Patent 7,553,818. (Claim text provided in prompt).
